Abstract
Brain angiotensin-(1-7) (Ang-(1-7)) concentration has been shown to be reduced and inversely correlated with tau pathology in a mouse model of Alzheimer’s disease (AD). In this study, to determine whether the concentration of Ang-(1-7) and the activity of its converting enzyme angiotensin-converting enzyme 2 were altered in plasma under AD context, the plasma samples from 110 AD patients and 128 age- and gender-matched controls were screened. In AD patients, the plasma concentration of Ang-(1-7) was significantly reduced (15.63±4.35pg/mL vs. 19.58±3.22pg/mL, P<0.001) and positively correlated with cognitive functions (R=0.66, P<0.001). Meanwhile, receiver-operating characteristic analysis showed that the Ang-(1-7) concentration in plasma could distinguish AD patients from controls with the sensitivity and specificity of 69.1% and 74.2%, respectively, when the optimal cut-off value (18.2 pg/mL) was chosen. These findings indicate that plasma Ang-(1-7) may represent a potential biomarker for AD diagnosis, and further suggest an involvement of this heptapeptide in the pathogenesis of this disease.
Keywords: Alzheimer’s disease, Renin-angiotensin system, angiotensin-(1-7), ACE2, plasma, biomarker.
Current Neurovascular Research
Title:Plasma Angiotensin-(1-7) is a Potential Biomarker for Alzheimer’s Disease
Volume: 13 Issue: 2
Author(s): Teng Jiang, Lan Tan, Qing Gao, Huan Lu, Xi-Chen Zhu, Jun-Shan Zhou and Ying-Dong Zhang
Affiliation:
Keywords: Alzheimer’s disease, Renin-angiotensin system, angiotensin-(1-7), ACE2, plasma, biomarker.
Abstract: Brain angiotensin-(1-7) (Ang-(1-7)) concentration has been shown to be reduced and inversely correlated with tau pathology in a mouse model of Alzheimer’s disease (AD). In this study, to determine whether the concentration of Ang-(1-7) and the activity of its converting enzyme angiotensin-converting enzyme 2 were altered in plasma under AD context, the plasma samples from 110 AD patients and 128 age- and gender-matched controls were screened. In AD patients, the plasma concentration of Ang-(1-7) was significantly reduced (15.63±4.35pg/mL vs. 19.58±3.22pg/mL, P<0.001) and positively correlated with cognitive functions (R=0.66, P<0.001). Meanwhile, receiver-operating characteristic analysis showed that the Ang-(1-7) concentration in plasma could distinguish AD patients from controls with the sensitivity and specificity of 69.1% and 74.2%, respectively, when the optimal cut-off value (18.2 pg/mL) was chosen. These findings indicate that plasma Ang-(1-7) may represent a potential biomarker for AD diagnosis, and further suggest an involvement of this heptapeptide in the pathogenesis of this disease.
Export Options
About this article
Cite this article as:
Jiang Teng, Tan Lan, Gao Qing, Lu Huan, Zhu Xi-Chen, Zhou Jun-Shan and Zhang Ying-Dong, Plasma Angiotensin-(1-7) is a Potential Biomarker for Alzheimer’s Disease, Current Neurovascular Research 2016; 13 (2) . https://dx.doi.org/10.2174/1567202613666160224124739
DOI https://dx.doi.org/10.2174/1567202613666160224124739 |
Print ISSN 1567-2026 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5739 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Potential of Selected Indian Herbs for COVID-19
Current Traditional Medicine Stem Cell Therapy in Chronic Ischemic Heart Dysfunction with and Without Viability
Cardiovascular & Hematological Disorders-Drug Targets Mitochondrial Dynamics: An Emerging Paradigm in Ischemia-Reperfusion Injury
Current Pharmaceutical Design Ezetimibe; More Than a Low Density Lipoprotein Cholesterol Lowering Drug? An Update After 4 Years
Current Vascular Pharmacology Genesis of Dihydropyrimidinone Calcium Channel Blockers: Recent Progress in Structure-Activity Relationships and Other Effects
Mini-Reviews in Medicinal Chemistry Editorial (Thematic Issue: The Long Way to a Successful Medical Therapy of Heart Failure with Beta-blockers in Children with Heart Disease)
Reviews on Recent Clinical Trials Anti-hyperglycemic Potential of Natural Products
Mini-Reviews in Medicinal Chemistry Positron Emission Tomography: Applications In Drug Discovery and Drug Development
Current Topics in Medicinal Chemistry The Role of Brain Gaseous Transmitters in the Regulation of the Circulatory System
Current Pharmaceutical Biotechnology Plant Troponoids: Chemistry, Biological Activity, and Biosynthesis
Current Medicinal Chemistry Dietary Fish Oil Concentrates Associated Health Benefits: A Recent Development of Cardiovascular Risk Reduction
Current Pharmaceutical Design Editorial: [Hot Topic: Establishment of the Australian Infectious Diseases Research Centre]
Current Drug Targets Cardiovascular Disease in the Rheumatic Diseases: How Systemic Inflammation May Contribute to Atherogenesis
Current Rheumatology Reviews Virtual Screening Against Obesity
Current Medicinal Chemistry Addiction Liability of Pharmacotherapeutic Interventions in Obesity
Current Pharmaceutical Design Utility of Intrapartum Transabdominal Ultrasound for the Correct Placement of Vacuum during Assisted Delivery
Current Women`s Health Reviews Preconditioning with Chronic Cerebral Hypoperfusion Reduces a Focal Cerebral Ischemic Injury and Increases Apurinic/Apyrimidinic Endonuclease/Redox Factor-1 and Matrix Metalloproteinase-2 Expression
Current Neurovascular Research Goal Directed Fluid Therapy
Current Pharmaceutical Design Vertical and Horizontal Convergences of Targeting Pathways in Combination Therapy with Baicalin and Jasminoidin for Cerebral Ischemia
CNS & Neurological Disorders - Drug Targets It’s Time for An Epigenomics Roadmap of Heart Failure
Current Genomics